Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 4 of 9
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
NCT02664181
Enhancing Quitline Services for African American Smokers
NCT03064971
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
NCT03121352
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
NCT03057613
PSA TOOL for Prostate Cancer Screening Discussions
NCT03135444
Adolescent and Young Adult Survivor Transition
NCT02948712
Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold
NCT03150758
Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer
NCT02794675
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
NCT02770391
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
NCT02669173
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
NCT02768389
Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal
NCT02790294
CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in AYA Cancers
NCT02916472
Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning
NCT02681614
The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning
NCT02842047
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
NCT02383433
Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0
NCT02756013
Online Information and Support for Distance Caregivers
NCT02666183
Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT02590107
Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors
NCT02763228
Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer
NCT02163317
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
NCT02319889
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
NCT02579811
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
NCT02581839
A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials
NCT02543541
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
NCT02065596
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity
NCT02566408
KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
NCT02337465
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
NCT02345460
A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer
NCT02613923
Building Caregiver Skills Using a Simulation-based Intervention for Care of Head and Neck Cancer
NCT02577237
Intra-Osseous Co-Transplant of UCB and hMSC
NCT02181478
Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
NCT02451124
Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program
NCT02419846
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
NCT02153450
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients
NCT02659345
Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans
NCT02417948
Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma
NCT02327390
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
NCT02388932
Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
NCT02387840
Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer
NCT02419807
Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
NCT02129218
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
NCT02392377
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
NCT02073097
Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods
NCT02375477
Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis
NCT02285738
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
NCT02342730
Enhanced Recovery After Surgery: A RCT of Perioperative Management of Gynecologic Patients
NCT02357251
Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials
NCT02129517
Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer
NCT02354326
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets.Report a data error.